Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Take your rubbish with u and go away!!
Read Rns from my December
Rua to disrupt $8billion industry
board member has done this before and is on the way to do the same,
He's is an American with FDA experience
20 December 2023
20 December 2023
RUA Life Sciences Plc
("RUA Life Sciences", the "Company" or the "Group")
Heart Valve Leaflet Material - Testing Update
RUA Life Sciences (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon?), today provides an update on recent developments of the RUA leaflet composite.
The objective for RUA Structural Heart during 2023 was to evaluate heart valve leaflet material and compare the performance of 100% polymeric valves with the novel composite developed by the Group. The computational modelling of the composite material at the design stage suggested that its mechanical properties would be ideal for heart valve leaflets.
Testing undertaken by RUA has demonstrated:
· Flex fatigue stability over 400m cycles
· Durability as a heart valve leaflet over 200m cycles
· Remarkable tensile strength properties exceeding both base fabric and polymer
· Similar tensile strength in multiple directions
· Highly flexible allowing improved valve efficiency.
· Narrow crimping profile allowing TAVR benefits
· Retention of ElastEon blood contacting properties such as calcification and thrombogenicity.
· Material very stable with no delamination during testing and high tear resistance.
Awaiting news on Heart valve
selling now is not the great idea when News is any day......
Read December Rns
Earl - thanks for the heads-up on GST.
Some saying 50p on the Rns on ADVFN..... won't disagree with them
looking at the $11 billion Market Size and growing fast this could become AIM most valuable companies in the future.
GLA and Dyor before its too late.
The Heart Valves Market in 2023 is US$ 11.55 billion, and is expected to reach US$28.45 billion by 2031 at a CAGR of 11.92%. The heart valves market is a dynamic and rapidly growing industry that plays a crucial role in the field of cardiovascular healthcare.4 Jan 2024
Late print buy just popped up 100k
mms tried hiding this
look how AGL risen on £150k contract announcement to
now RUA Announcement would be in $10m+ minimum because heart valve market is worth multiple of billion dollars
Bill Brown, Chairman of RUA said: "The mutual benefits of this partnership with Corcym are transformational for RUA. Not only does it validate our belief in the product range but it is backed up with Corcym's capacity and capabilities to make the graft range available to heart surgeons globally."
Christian Mazzi , CEO of Corcym added : "Corcym is excited to partner with an innovative company like RUA to commercialise the aortic graft range. Corcym's mission is to help cardiac surgeons treat patients better, today and in the future, and RUA's aortic graft range will be an important addition to the product portfolio we can offer Heart Surgeons worldwide
Talks for heart valve, unique design and patented
Read Rns
Who cares? If you can’t make your mind up here then give up. Shrouded in 4 year placing protection- in this market 😎
There's no evidence of persistent selling here. That was a reference to the historic selling by Ahmati, which is long gone.
Mostly buying last few sessions but still in the red?
In Intra's excellent post , few have picked up this huge USP, need & urgency - total reliance on Australian and NZ cows.
"One of these has signed an MTA to look at RUA’s new composite material which, based on its own benchtop trials, it claims is considerably stronger, tear resistant yet thinner and flexible, ideal for TAVR and all improvements over current technologies which rely on animal tissue sourced from cows in Australia and New Zealand, the only BSE-free herds in the world. You can see why the majors will eventually want to develop something new that doesn’t rely on a risky supply chain such as these animals. If BSE invaded Australia, these majors would freak out."
They have £4m you idiot
No. They’ve had the material to test from January. So factoring in Xmas holidays and back to work probably didn’t start until a few days into jan.
You think testing is that quick?
Takes software companies weeks just to test some web changes
This is heart valve and multi billionaire companies work slower than agile companies like RUA. So a 3-6 month testing window is to be fully expected
Read all about it!
2p coming!
Yep. Being cashed up, it can take as long as it takes. As it is a crucial product, it has to be mega tested - worth it for the upside . The gap up will be awesome with the small share number.!
Unfortunately Jimzi there is nothing to talk about. At the moment it's just a waiting game. The major heart valve company have had the material for testing purposes for quite a long time now. I believe they've had it for a lot longer than the the RNS in December. I think the RNS was only released because there was mention of it in the presentation and that's what triggered the RNS.
Still here, just not much to talk about atm. Investing is very boring but can be highly lucrative.
Where is everyone
It must be hard to buy
Only 7 trades lol
Be interested to know when people are expecting the update on testing to come? As I understand things this will likely be the significant event that will drive the share to new highs (or lows!). The update on 5th was great to hear - but got the impression news may still be some time away.
Big week ahead. Was near impossible to buy in any great volume last week.
1 mms have popped up at 15